Frontier Medicines to Spotlight Lead Candidate, Novel Dual KRASG12C Inhibitor FMC-376, and the Frontier™ Platform at the 2023 AACR Annual Meeting

Frontier Medicines to Spotlight Lead Candidate, Novel Dual KRASG12C Inhibitor FMC-376, and the Frontier™ Platform at the 2023 AACR Annual Meeting March 14, 2023 BOSTON and SOUTH SAN FRANCISCO, Calif. — Frontier Medicines Corporation, a precision medicine company seeking to unlock the proteome to advance breakthrough therapies against otherwise undruggable disease-causing targets, today announced upcoming presentations featuring preclinical data on its novel dual KRAS G12C inhibitor FMC-376 and advances from the Frontier™ Platform. These data will be presented at the upcoming American Association for Cancer Research (AACR) Annual Meeting taking place April 14 th -19 th in Orlando, Florida. Preclinical data unveiling FMC-376’s discovery and unique mode of action will be featured in an oral mini-symposium on Small Molecule Therapeutic Agents on April 16 th , followed by a presentation on the Frontier Platform in an April 18 th poster session. “Decades after the human genome project, there remains a high unmet need for effective and durable breakthrough precision medicines targeting previously undruggable targets like KRAS,” said Chris Varma, Ph.D., Frontier’s co-founder, chairman, and CEO. “We are excited to share data showing how our novel dual inhibitor FMC-376 is designed to rapidly and directly shut down both active and inactive KRAS G12C . These findings further validate the ability of the Frontier Platform to unlock the proteome for the discovery of treatments that can potentially create a better future for people with cancer and other serious conditions.” Details on the presentations are as follows: Presentation Information Title: Discovery of FMC-376 a novel orally bioavailable inhibitor of activated KRAS G12C Abstract Number: 1142 Oral Session Title: Small Molecule Therapeutic Agents Session Date and Time: Sunday, April 16, 2023, 3-5 p.m. ET Title: Combining chemoproteomics with machine learning identifies functionally active covalent fragments for hard-to-drug cancer drivers Abstract Number: 5333 Oral Session Title: High-throughput Screening, Lead Identification and Optimization, and in Silico Drug Discovery Session Date and Time: Tuesday, April 18, 2023, 1:30-5 p.m. ET About Frontier Medicines Frontier Medicines is a precision medicine company that has pioneered a powerful drug discovery engine, the Frontier™ Platform, designed to generate medicines against disease-causing proteins previously considered undruggable. The company is deploying its technologies in chemoproteomics, covalent drug discovery, and machine learning to develop potentially groundbreaking medicines for genetically-defined patient populations, starting in cancer. Frontier is advancing a deep pipeline of wholly-owned precision medicines against the most important drivers of cancer. The company’s lead candidate, FMC-376, is a dual inhibitor of active and inactive KRAS G12C . By completely blocking both forms of the KRAS mutation, FMC-376 has the potential to overcome the non-response and resistance seen with single-acting KRAS G12C inhibitors. For more information on how Frontier is boldly advancing science to defeat disease, visit www.frontiermeds.com and follow us on LinkedIn and Twitter . Our Locations Boston Office 451 D St., Suite 207 Boston, MA 02210 South San Francisco Office 151 Oyster Point Blvd., 2nd Floor South San Francisco, CA 94080 About Our Mission Executive Team Partners & Investors Board of Directors Scientific Advisory Board Science & Platforms Scientific Approach The Frontier™ Platform Chemoproteomics Artificial Intelligence Precision Pipeline Precision-based Pipeline FMC-376: KRAS G12C FMC-220: p53 Y220C FMC-242: PI3Kα -RAS Newsroom Press Releases Publications News Articles Media Center © 2026 Frontier Medicines FRONTIER MEDICINES and are registered trademarks of Frontier Medicines Corporation and are registered in the United States and other countries. Access to Investigational Therapies Contact Careers Terms of Use Privacy Policy Site Map About Science & Platforms Precision Pipeline Newsroom Access to Investigational Therapies Contact Careers Terms of Use Privacy Policy Site Map Our Locations Boston Office 451 D St., Suite 207 Boston, MA 02210 South San Francisco Office 151 Oyster Point Blvd., 2nd Floor South San Francisco, CA 94080 © 2026 Frontier Medicines Frontier Medicines Presents New Preclinical Data on its Development Candidate,... Frontier Medicines Expands Leadership Team with Addition of Christo Shalish... Scroll to top We use cookies to give you the best online experience. By using our website, you agree to our use of cookies in accordance with our privacy policy. Accept Cookie Settings Cookie and Privacy Settings How we use cookies We may request cookies to be set on your device. We use cookies to let us know when you visit our websites, how you interact with us, to enrich your user experience, and to customize your relationship with our website. Click on the different category headings to find out more. You can also change some of your preferences. Note that blocking some types of cookies may impact your experience on our websites and the services we are able to offer. Essential Website Cookies These cookies are strictly necessary to provide you with services available through our website and to use some of its features. Because these cookies are strictly necessary to deliver the website, refusing them will have impact how our site functions. You always can block or delete cookies by changing your browser settings and force blocking all cookies on this website. But this will always prompt you to accept/refuse cookies when revisiting our site. We fully respect if you want to refuse cookies but to avoid asking you again and again kindly allow us to store a cookie for that. You are free to opt out any time or opt in for other cookies to get a better experience. If you refuse cookies we will remove all set cookies in our domain. We provide you with a list of stored cookies on your computer in our domain so you can check what we stored. Due to security reasons we are not able to show or modify cookies from other domains. You can check these in your browser security settings. Check to enable permanent hiding of message bar and refuse all cookies if you do not opt in. We need 2 cookies to store this setting. Otherwise you will be prompted again when opening a new browser window or new a tab. Click to enable/disable essential site cookies. Other external services We also use different external services like Google Webfonts, Google Maps, and external Video providers. Since these providers may collect personal data like your IP address we allow you to block them here. Please be aware that this might heavily reduce the functionality and appearance of our site. Changes will take effect once you reload the page. Google Webfont Settings: Click to enable/disable Google Webfonts. Google Map Settings: Click to enable/disable Google Maps. Google reCaptcha Settings: Click to enable/disable Google reCaptcha. Vimeo and Youtube video embeds: Click to enable/disable video embeds. Privacy Policy You can read about our cookies and privacy settings in detail on our Privacy Policy Page. Accept All Cookies Hide notification only

The release as fetched from its publisher. frontiermeds.com ↗